IDH305
Total Payments
$948,979
Transactions
14
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $77,749 | 2 | 0 |
| 2019 | $81,545 | 3 | 0 |
| 2018 | $184,887 | 5 | 0 |
| 2017 | $604,797 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $948,979 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I STUDY OF IDH305 IN PATIENTS WITH ADVANCED MALIGNANCIES THAT HARBOR IDH1R132 MUTATIONS | Novartis Pharmaceuticals Corporation | $921,485 | 0 |
| A PHASE I OPEN LABEL MULTICENTER DOSE FINDING STUDY OF IDH305 WITH STANDARD OF CARE IN IDH1 MUTANT ACUTE MYELOID LEUKEMIA | Novartis Pharmaceuticals Corporation | $27,494 | 0 |
Top Doctors Receiving Payments for IDH305
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $948,979 | 14 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $948,979
Product Information
- Type Drug
- Total Payments $948,979
- Total Doctors 0
- Transactions 14
About IDH305
IDH305 is a drug associated with $948,979 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $77,749 was paid across 2 transactions to 0 doctors.
The most common payment nature for IDH305 is "Unspecified" ($948,979, 100.0% of total).
IDH305 is associated with 2 research studies, including "A PHASE I STUDY OF IDH305 IN PATIENTS WITH ADVANCED MALIGNANCIES THAT HARBOR IDH1R132 MUTATIONS" ($921,485).